» Articles » PMID: 26676777

Signatures in Simian Immunodeficiency Virus SIVsmE660 Envelope Gp120 Are Associated with Mucosal Transmission but Not Vaccination Breakthrough in Rhesus Macaques

Overview
Journal J Virol
Date 2015 Dec 18
PMID 26676777
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Mucosal surfaces are vulnerable to human immunodeficiency virus (HIV)/simian immunodeficiency virus (SIV) infection and thus are key sites for eliciting vaccine-mediated protection. Vaccine protocols carried out at the Yerkes Primate Research Center utilized SIVmac239-based immunization strategies with intrarectal and intravaginal SIVsmE660 challenge of rhesus macaques. We investigated whether there were genetic signatures associated with SIVsmE660 intrarectal and intravaginal transmissions in vaccinated and unvaccinated monkeys. When transmitted/founder (T/F) envelope (Env) sequences from 49 vaccinated and 15 unvaccinated macaques were compared to each other, we were unable to identify any vaccine breakthrough signatures. In contrast, when the vaccinated and control T/F Envs were combined and compared to the challenge stock, residues at gp120 positions 23, 45, 47, and 70 (Ile-Ala-Lys-Asn [I-A-K-N]) emerged as signatures of mucosal transmission. However, T/F Envs derived from intrarectal and intravaginal infections were not different. Our data suggest that the vaginal and rectal mucosal environments both imposed a strong selection bias for SIVsmE660 variants carrying I-A-K-N that was not further enhanced by immunization. These findings, combined with the strong conservation of A-K-N in most HIV-2/SIVsmm isolates and the analogous residues in HIV-1/SIVcpz isolates, suggest that these residues confer increased transmission fitness to SIVsmE660.

Importance: Most HIV-1 infections occur across a mucosal barrier, and it is therefore important to understand why these sites are vulnerable and how to protect them with a vaccine. To gain insight into these questions, we studied rhesus macaques that were vaccinated with SIVmac239 and unvaccinated controls to determine whether the SIVsmE660 viral variants that infected these two groups were different. We did not find differences between viral variants in the absence versus presence of vaccination-induced immunity, but we did find that the SIVsmE660 viral variants that infected the monkeys, regardless of vaccination, were different from the dominant population found in the viral challenge inoculum. Our data suggest that the mucosal environments of the vagina and rectum both impose a strong selection for the SIVsmE660 variants in the challenge inoculum that are most like SIV and HIVs that circulate in nature.

Citing Articles

A comprehensive insight on the challenges for COVID-19 vaccine: A lesson learnt from other viral vaccines.

Soloman Singh R, Singh A, Masih G, Batra G, Sharma A, Joshi R Heliyon. 2023; 9(6):e16813.

PMID: 37303517 PMC: 10245239. DOI: 10.1016/j.heliyon.2023.e16813.


Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants.

Burton S, Spicer L, Charles T, Gangadhara S, Reddy P, Styles T J Virol. 2019; 93(7).

PMID: 30651354 PMC: 6430525. DOI: 10.1128/JVI.01846-18.


A high throughput lentivirus sieving assay identifies neutralization resistant Envelope sequences and predicts in vivo sieving.

Iwamoto N, Mason R, Hu J, Ransier A, Welles H, Song K J Immunol Methods. 2018; 464:64-73.

PMID: 30389575 PMC: 6322957. DOI: 10.1016/j.jim.2018.10.013.


Control of Heterologous Simian Immunodeficiency Virus SIV Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques.

Singh S, Ramirez-Salazar E, Doueiri R, Valentin A, Rosati M, Hu X J Virol. 2018; 92(15).

PMID: 29793957 PMC: 6052320. DOI: 10.1128/JVI.00281-18.


Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys.

Keele B, Li W, Borducchi E, Nkolola J, Abbink P, Chen B Nat Commun. 2017; 8:15740.

PMID: 28580942 PMC: 5465370. DOI: 10.1038/ncomms15740.


References
1.
Fouts T, Bagley K, Prado I, Bobb K, Schwartz J, Xu R . Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. Proc Natl Acad Sci U S A. 2015; 112(9):E992-9. PMC: 4352796. DOI: 10.1073/pnas.1423669112. View

2.
Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B . Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol. 2005; 79(10):6528-31. PMC: 1091724. DOI: 10.1128/JVI.79.10.6528-6531.2005. View

3.
Derdeyn C, Decker J, Bibollet-Ruche F, Mokili J, Muldoon M, Denham S . Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science. 2004; 303(5666):2019-22. DOI: 10.1126/science.1093137. View

4.
Stone M, Keele B, Ma Z, Bailes E, Dutra J, Hahn B . A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251. J Virol. 2010; 84(14):7083-95. PMC: 2898254. DOI: 10.1128/JVI.00481-10. View

5.
Cervasi B, Carnathan D, Sheehan K, Micci L, Paiardini M, Kurupati R . Immunological and virological analyses of rhesus macaques immunized with chimpanzee adenoviruses expressing the simian immunodeficiency virus Gag/Tat fusion protein and challenged intrarectally with repeated low doses of SIVmac. J Virol. 2013; 87(17):9420-30. PMC: 3754116. DOI: 10.1128/JVI.01456-13. View